Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

Targeted therapy and immunotherapy have become mainstream in cancer treatment.
However, only patient subsets benefit from these expensive therapies, and often responses …

In the last decade, cancer immunotherapies have produced impressive therapeutic results.
However, the potency of immunotherapy is tightly linked to immune cell infiltration within the …

Cancer is one of the most common diseases and causes of death worldwide. Since common
treatment approaches do not yield acceptable results in many patients, developing …

Targeted therapy is a fast evolving treatment strategy to reduce unwanted damage to
healthy tissues, while increasing efficacy and specificity. Driven by state-of-the-art …

Fc-less bispecific T-cell engagers have reached the immuno-oncology market but
necessitate continual infusion due to rapid clearance from the circulation. This work …

There is an urgent need to identify new cellular targets to expand the repertoire, potency and
safety of cancer therapeutics. Neonatal Fc Receptor (FcRn)-driven cellular recycling plays a …

Cancer is a heterogeneous disease, requiring treatment tailored to the unique phenotype of
the patient's tumor. Monoclonal antibodies (mAbs) and variants thereof have enabled …

Breast cancer (BC) treatment has traditionally been challenging due to tumor heterogeneity.
Bispecific antibodies (bsAbs) offer a promising approach for overcoming these challenges …